Sign in

ATOS on Nasdaq

Atossa Therapeutics (United States)

Logo: atossatherapeutics.com4

Atossa Therapeutics (United States) is an American pharmaceutical preparations company based in Seattle, founded in 2009.1 Its website says: “Building on our established foundation in breast cancer, we are leveraging the pro-estrogenic or anti-estrogenic attributes of SERM/D compound to expand our clinical research and developments beyond breast cancer and into rare diseases such as McCune-Albright Syndrome and Duchenne Muscular Dystrophy.”4

Price unavailable

Last updated Oct 21, 2026.

Overview

2009Founded1

Compare with Aditxt, Inc., One World Products, Inc. or Processa Pharmaceuticals, Inc., or pick any stock.

  • TickerATOS on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSeattle1
  • Websiteatossatherapeutics.com
  • Legal formDelaware corporation1
  • Incorporated inDE5
  • Business address1448 Nw Market Street, Suite 500, Seattle, Wa 981075
  • Filer categoryNon-accelerated filer, Smaller reporting company5
  • LEI549300QRKP1JTNHD23663
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressC/O Corporation Service Company, 19808 Wilmington, United States3
  • Registered withDivision of Corporations, Department of State, 46822363

See how the biggest companies compare on our leaderboards

Atossa Therapeutics (United States) image from its website
Image: atossatherapeutics.com4

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income67891011-$37.1M in 2025+115% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$17.3M-$17.3M20192020: -$14.6M-$14.6M2020−15%2021: -$20.5M-$20.5M2021+40%2022: -$27.7M-$27.7M2022+35%2023: -$31.4M-$31.4M2023+13%2024: -$27.6M-$27.6M2024−12%2025: -$37.1M-$37.1M2025+34%
Net income67891011-$34.8M in 2025+102% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$17.2M-$17.2M20192020: -$17.8M-$17.8M2020+3%2021: -$20.6M-$20.6M2021+16%2022: -$27.0M-$27.0M2022+31%2023: -$30.1M-$30.1M2023+12%2024: -$25.5M-$25.5M2024−15%2025: -$34.8M-$34.8M2025+36%

Every line of the income statement as filed: the last 2 fiscal years, latest first.11

Period ending2025-12-312024-12-31
Research and development$21.2M$14.1M
General and administrative$16.0M$13.5M
Total operating expenses$37.1M$27.6M
Operating loss-$37.1M-$27.6M
Impairment charge on investment in equity securities$0-$1.7M
Interest income$2.4M$4.0M
Other expense, net-$6.0K-$223.0K
Loss before income taxes-$34.8M-$25.5M
Income taxes benefit$0$0
Net loss-$34.8M-$25.5M
Net loss per share of common stock - basic (in dollars per share)-$4.04-$3.04
Net loss per share of common stock - diluted (in dollars per share)-$4.04-$3.04
Weighted average shares outstanding used to compute net loss per share- basic (in shares)8.6M shares8.4M shares
Weighted average shares outstanding used to compute net loss per share - diluted (in shares)8.6M shares8.4M shares

Compare Atossa Therapeutics (United States) with another company

Corporate structure

Atossa Therapeutics (United States) sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Atossa Therapeutics (United States)

  • VANGUARD GROUP INC Filed SCHEDULE 13G/A on Atossa Therapeutics (United States), latest Jul 29, 2025 (5 filings since Feb 9, 2022)
  • BlackRock Filed SCHEDULE 13G/A on Atossa Therapeutics (United States), latest Jul 16, 2025 (5 filings since Feb 4, 2022)
  • CVI Investments, Inc. Filed SCHEDULE 13G/A on Atossa Therapeutics (United States), latest Feb 7, 2025 (2 filings since Feb 14, 2022)
  • Empery Asset Management, LP Filed SC 13G/A on Atossa Therapeutics (United States), latest Jan 13, 2022
  • Atossa Therapeutics (United States) Seattle, Washington, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Atossa Therapeutics (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$41.3M11 Dec 31, 2025$71.1M11 Dec 31, 2024−41.9%

Properties, in its own words

We have an operating lease with 1448 NW Market Street Tenant LLC for office space in Seattle, Washington. The lease commencement date was November 1, 2025 and we agreed to pay $3 thousand per month for 13 months.

Item 2 of the 10-K filed Mar 25, 2026.14

Leadership

Who has led Atossa Therapeutics (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Steven C. Quay2012–now

President

  1. Steven C. Quay2015–now

Chief financial officer

  1. Kyle Guse2013–2023
  2. Heather Rees2025–now

Chief operating officer

  1. Scott Youmans2015
2010201520202025
Board members and other officers (15)

Former names

  • ATOSSA GENETICS INCMar 30, 2010 to Nov 13, 20195

Timeline

  1. Oct 9, 20268-K Entered a material agreement; Change to shareholders' rights; Other events32
  2. Sep 29, 20268-K Other events33
  3. Sep 18, 20268-K Regulation FD disclosure34
  4. Aug 7, 20268-K Results of operations35
  5. Jun 11, 20268-K Entered a material agreement36
  6. May 8, 20268-K Shareholder vote37
  7. May 8, 20268-K Financial statements and exhibits38
  8. Apr 16, 20268-K Other events39
  9. Mar 25, 20268-K Financial statements and exhibits40
  10. Feb 20, 20268-K Entered a material agreement; Ended a material agreement41
  11. Feb 17, 20268-K Listing notice or transfer42
  12. Feb 11, 20268-K Regulation FD disclosure43
  13. Nov 7, 2012New chief executive Steven C. Quay becomes CEO15
  14. 2009Founded Founded1

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($1.05) a share, on Nov 12, 2025.44

When it reported results

  1. Aug 7, 2026Reported quarterly or annual results35
  2. Jan 9, 2026Reported quarterly or annual results45
  3. Nov 12, 2025Reported quarterly or annual results46
  4. Aug 12, 2025Reported quarterly or annual results47
  5. May 13, 2025Reported quarterly or annual results48
  6. Mar 25, 2025Reported quarterly or annual results49
  7. Nov 12, 2024Reported quarterly or annual results50
  8. Aug 12, 2024Reported quarterly or annual results51

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

180 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 68 major events, 54 insider forms, 13 large holders, 25 other. The latest 20:

  1. Oct 9, 20268-K EDGAR
  2. Sep 29, 20268-K EDGAR
  3. Sep 18, 20268-K EDGAR
  4. Aug 7, 20268-K EDGAR
  5. Aug 7, 202610-Q EDGAR
  6. Jun 12, 2026424B5 EDGAR
  7. Jun 11, 20268-K EDGAR
  8. May 14, 20264 EDGAR
  9. May 14, 20264 EDGAR
  10. May 14, 20264 EDGAR
  11. May 14, 20264 EDGAR
  12. May 14, 20264 EDGAR
  13. May 14, 20264 EDGAR
  14. May 8, 20268-K EDGAR
  15. May 8, 202610-Q EDGAR
  16. May 8, 20268-K EDGAR
  17. Apr 16, 20268-K EDGAR
  18. Mar 31, 20264 EDGAR
  19. Mar 30, 20264 EDGAR
  20. Mar 30, 2026ARS EDGAR

The 180 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

5 open-market trades by officers, directors and large owners since October 2021: 4 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 21, 2025QUAY STEVEN CPresident & CEOBuy11,239$0.88$9.9KForm 4
Mar 26, 2025Remmel H. LawrenceDirectorBuy10,000$0.70$7.0KForm 4
Apr 10, 2024Finn JonathanDirectorBuy25,000$1.77$44.2KForm 4
Nov 15, 2023WEAVER GREGORY LFormer EVP, CFO, & DirectorSale50,000$0.65$32.5KForm 4
Jun 20, 2023WEAVER GREGORY LFormer EVP, CFO, & DirectorBuy50,000$0.97$48.5KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Steven C. Quay, M.D., Ph. D.Chairman, President and75$731.0K$2.5M56
2025Heather Rees, CPA (Inactive)Former Chief Financial Officer$482.2K$981.7K56
2025Mark J. DanielChief Financial Officer50$72.5K$536.5K56
2024Chief Executive Officer$705.9K$2.8M56
2024Heather Rees, CPA (Inactive)Former Chief Financial Officer$402.5K$1.1M56

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 32. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC361,747$698.2K0.0%+12,651
Ameriprise Financial Inc258,234$498.4K0.0%+3,100
BlackRock, Inc.164,358$317.2K0.0%+31,189
Renaissance Technologies LLC132,043$254.8K0.0%+23,036
Geode Capital Management, LLC92,382$178.3K0.0%−4,679
UBS Group AG82,620$159.5K0.0%−9,414
Jane Street Group, LLC56,602$109.2K0.0%New
Vanguard Fiduciary Trust Co52,583$101.5K0.0%+348
Millennium Management LLC46,508$89.8K0.0%−20,231
State Street Corp39,761$76.7K0.0%No change
Northern Trust Corp20,249$39.1K0.0%+1,025
Susquehanna International Group, Llp15,574$30.1K0.0%New
Morgan Stanley12,345$23.8K0.0%−3,857
Vanguard Global Advisers, LLC3,089$6.0K0.0%No change
Royal Bank Of Canada1,994$4.0K0.0%+1,350
Jones Financial Companies Lllp2,061$3.9K0.0%No change
MCF Advisors LLC1,066$2.1K0.0%New
Osaic Holdings, Inc.587$1.1K0.0%No change
Jpmorgan Chase & Co390$7720.0%+7
Rockefeller Capital Management L.P.333$6430.0%−20
Wells Fargo & Company/mn228$4400.0%−68
SBI Securities Co., Ltd.148$2860.0%+35
Harbour Investments, Inc.110$2120.0%No change
TD Waterhouse Canada Inc.103$2100.0%No change
Bnp Paribas Financial Markets87$1680.0%−11

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Atossa Therapeutics (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARATOSSA THERAPEUTICS, INC.2
  • CIK0001488039
  • Employer ID (EIN)26-475320814
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company14
  • Incorporated inDelaware14
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address1448 Nw Market Street, Suite 500, Seattle, WA 981072
  • Phone206.588.02562
  • Shares outstanding9,979,298 as of Jul 31, 202613
  • Public float$107.1M as of Jun 30, 202514
  • AuditorEY, Seattle, Washington PCAOB ID 42; no auditor attestation of internal control over financial reporting14
  • On EDGAR sinceMar 30, 20102
  • Filings641 in all: 8-K (173), 4 (138), 10-Q (42), CORRESP (39), S-1/A (28), UPLOAD (21), EFFECT (20), 3 (19)2
    All 40 form types

    DEF 14A (16), 424B3 (15), 10-K (14), SC 13G (14), S-1 (13), 424B5 (10), SC 13G/A (10), PRE 14A (8), 10-Q/A (6), S-3 (6), DEFA14A (5), ARS (4), FWP (4), S-8 (4), 8-K/A (3), D (3), POS AM (3), SCHEDULE 13G/A (3), 4/A (2), 424B4 (2), 5 (2), 8-A12B (2), D/A (2), RW (2), 10-K/A (1), 424B2 (1), CERTNAS (1), CT ORDER (1), DEL AM (1), S-3MEF (1), SC 13D (1), SC 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 25, 2026
    Quarterly report (10-Q) Aug 7, 2026
    Proxy statement (DEF 14A) Mar 30, 2026
    Latest 8-K (8-K) Oct 9, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.18 par valueATOSNasdaq

From the cover page of the 10-K filed Mar 25, 2026 (Section 12(b) of the Exchange Act).14

Risk factors and legal proceedings

The risks Atossa Therapeutics (United States) names in Item 1A of its 10-K filed Mar 25, 2026: 53 risks under these headings, as written.14

  • Risks Related to our Business
  • Risks Related to our Intellectual Property
  • Risks Related to Our Industry
  • Risks Related to the Securities Markets and Investment in our Securities.
  • We have a history of operating losses and expect to continue to incur losses in the future, and, as such, an investor cannot assess our profitability or performance based on past results.
  • We have not established sources of ongoing revenue to cover operating costs and allow us to continue as a going concern.
  • If we do not raise additional capital, we anticipate liquidity issues after the next twelve months and we may not continue as a going concern.
  • Macroeconomic factors could adversely impact our business and our ability to raise additional capital.
  • We will need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms.
  • We may expend our capital resources in ways that you do not agree or that do not produce stockholder value.
  • Any products we may develop may never achieve significant commercial market acceptance.
  • We may be unable to establish sales, marketing and commercial supply capabilities.
The other 44 risks
  • The loss of the services of our Chief Executive Officer could adversely affect our business.
  • Our acquisitions of, collaborations with, licenses with and investments in, other businesses may not yield expected benefits, and our inability to successfully integrate these transactions may negatively impact our business, financial condition, and results of operations.
  • We may experience difficulty in locating, attracting and retaining experienced and qualified personnel, which could adversely affect our business.
  • Compounds and methods that appear promising in research and development may fail to reach later stages of development for a number of reasons, including, among others, that clinical trials may take longer to complete than expected or may not be completed at all, and interim, top-line or preliminary clinical trial data reports may ultimately differ from actual results once data are more fully evaluated.
  • We may not obtain or maintain the regulatory approvals required to develop or commercialize some or all of our products.
  • We have received Rare Pediatric Disease designation by the FDA for (Z)-Endoxifen for Duchenne Muscular Dystrophy. However, Rare Pediatric Disease designation for any of our product candidates does not guarantee that the NDA for the product will qualify for a priority review voucher upon approval, and it does not lead to a faster development or regulatory review process, or increase the likelihood that our product candidates will receive marketing approval.
  • We may not enjoy the market exclusivity benefits of our orphan drug designations.
  • We are developing our products for patients who are severely ill, and patient deaths that occur in our clinical trials could negatively impact our business even if such deaths are not shown to be related to our drugs.
  • We are dependent on third party service providers for a number of critical operational activities including, in particular, for the manufacture and testing of our products and associated supply chain operations, as well as for clinical trial activities. Any failure or delay in these undertakings by third parties could harm our business.
  • We may encounter delays in our clinical trials or may not be able to conduct our trials in a timely manner.
  • Our clinical trials may fail to demonstrate adequately the efficacy and safety of our product candidates, which would prevent or delay regulatory approval and commercialization.
  • Our products and services may expose us to possible litigation and product liability claims.
  • The deployment of AI in our or our collaborators' product candidates could adversely affect our business, reputation or financial results.
  • Business disruptions, including natural disasters, severe weather and pandemics, could seriously harm our future revenue and financial condition and increase our costs and expenses.
  • We maintain our cash at financial institutions, often in balances that exceed federally-insured limits. The failure of financial institutions could adversely affect our ability to pay our operational expenses or make other payments.
  • Our ability to use net operating loss carryforwards and research tax credits to reduce future tax payments may be limited or restricted.
  • If we, or our wholly-owned subsidiary, lose our ability to operate in Australia, or if our subsidiary is unable to benefit from the past or future R&D tax rebates available under current Australian regulations, our business and results of operations could be harmed.
  • If we are not able to protect our proprietary technology, others could compete against us more directly, which would harm our business.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.
  • We may not be able to protect our intellectual property rights throughout the world.
  • Our current patent portfolio may not include all patent rights needed for the full development and commercialization of our products. We cannot be sure that patent rights we may need in the future will be available for license on commercially reasonable terms, or at all.
  • Third-party claims alleging intellectual property infringement may prevent or delay our drug discovery and development efforts.
  • We cannot assure you that our current or future products will not infringe on existing or future patents. We may not be aware of patents that have already been issued that a third party might assert are infringed by one of our current or future products.
  • We may use PTAB proceedings to challenge the validity of third-party intellectual property.
  • We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
  • We may be unable to adequately prevent disclosure of trade secrets and other proprietary information.
  • Legislative or regulatory reforms may make it more difficult and costly for us to obtain regulatory approval of our product candidates and to manufacture, market and distribute our products after approval is obtained.
  • Disruptions at the FDA and other government agencies could negatively affect the review of our regulatory submissions, which could negatively impact our business.
  • Our inadvertent or unintentional failure to comply with the complex government regulations concerning patients' privacy, other data subjects, and of medical records could subject us to fines and adversely affect our reputation.
  • Significant disruptions in our information technology systems or breaches of data security could adversely affect our business.
  • The failure to comply with complex federal and state laws and regulations related to submission of claims for services could result in significant monetary damages and penalties and exclusion from the Medicare and Medicaid programs.
  • We face significant competition from other biotechnology and pharmaceutical companies.
  • Our employees and third-party partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
  • Our business involves risk associated with handling hazardous and other dangerous materials.
  • Our shares of common stock are listed on the Nasdaq Capital Market, but we cannot guarantee that we will be able to maintain compliance with the continued listing standards or satisfy the continued listing standards going forward, which could make it more difficult for our stockholders to sell their shares.
  • The sale of a substantial number of shares of our common stock into the market may cause substantial dilution to our existing stockholders and the sale, actual or anticipated, of a substantial number of shares of common stock could cause the price of our common stock to decline.
  • The trading price of our common stock has been and is likely to continue to be volatile.
  • We have never paid dividends, and we do not anticipate paying dividends in the future.
  • The ownership of our common stock may become concentrated among a small number of stockholders, and if our principal stockholders, directors and officers choose to act together, they may be able to significantly influence management and operations, which may prevent us from taking actions that may be favorable to stockholders.
  • If we are unable to implement and maintain effective internal control over financial reporting in the future, investors may lose confidence in the accuracy and completeness of our financial reports and the trading price of our common stock may be negatively affected.
  • The anti-takeover provisions in our governing documents and Delaware law could delay or prevent a change in control which could reduce the market price of our common stock and could prevent or frustrate attempts by our stockholders to replace or remove our current management and the current Board.
  • Our Amended and Restated Certificate of Incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes.
  • If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the price of our common stock and trading volume could decline.

Legal proceedings

We are, and from time to time we may become, involved in legal proceedings or be subject to claims arising in the ordinary course of our business. For a discussion of our legal proceedings, refer to Note 13 to the Consolidated Financial Statements. We are not presently a party to any other legal proceedings that in the opinion of our management, if determined adversely to us, would individually or taken together have a material adverse effect on our consolidated results of operations, financial condition or cash flows.

The opening of Item 3, Legal Proceedings.14

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
    SEC EDGAROther events
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
    SEC EDGAROther events
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56